Estimates Revisions MBX Biosciences, Inc.
Equities
MBX
US55287L1017
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.02 USD | -1.29% |
|
+7.32% | +18.10% |
| 05-07 | MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-22 | PMV Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- MBX Stock
- Consensus MBX Biosciences, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition